Phase 1b/2a Program Commences for RVX-208



    TSX Exchange Symbol: RVX

    CALGARY, Aug. 25 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce that the Phase 1b/2a program for
the study of RVX-208 in subjects with normal lipids and those with low
high-density lipoprotein (HDL) cholesterol has proceeded according to plan.
    "We are very excited about moving forward into this important 28-day
study with RVX-208. Our previous clinical study demonstrated that RVX-208 was
safe, tolerable and had favorable pharmacokinetics," stated Dr. Allan Gordon,
Senior Vice President Clinical Development of Resverlogix. "This trial will
continue to examine safety and tolerance as well it is a proof of principle
study for ApoA-I production and HDL functionality. Approximately half of the
subjects will have low levels of HDL cholesterol, a condition associated with
significant increased risk of cardiovascular disease," added Dr. Gordon.
    "The ensuing Phase 1b/2a study comprises several novel facets to expedite
the clinical process for RVX-208 and its eventual registration as a drug,"
stated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey
further confirmed, "Along with the required regulatory provisions that must be
addressed such as safety, tolerance and pharmacokinetics, the study also will
measure key reverse cholesterol transport markers which RVX-208 impacts. These
are exclusive favorable features that make this drug unique among its
competitors."
    RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208
is the only novel small molecule that is specifically designed to increase
ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport.

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.

    This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

    %SEDAR: 00019253E




For further information:

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com;
Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: (403)
254-9252, Email: Sarah@resverlogix.com; Website: www.resverlogix.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890